Waldenström's macroglobulinemia (WM) is a lymphoplasmacytic disorder with associated monoclonal gammopathy. A wide variety of neuropathies can be associated with WM, but most commonly it is a mild length-dependent sensory neuropathy of unclear etiology. Rituximab is a monoclonal antibody which suppresses mature B-cell populations. It has increasingly been used in wide applications including WM, especially in those cases with severe neuropathy. The highlighted case provides an example of rituximab treatment complication in a WM patient with mild sensory neuropathy that evolved to multiple mononeuropathies with features of systemic vasculitis and unusual conversion of type I to type II cryoglobulinemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jns.2007.04.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Waldenström Macroglobulinemia-Induced Cardiac Amyloid Light Chain Amyloidosis.
Ochsner J
January 2024
Division of Cardiology, Baylor Scott & White Medical Center, Temple, TX.
Waldenström macroglobulinemia is a rare cancer of plasma cells characterized by the excessive production of immunoglobulin M (IgM). IgM-associated systemic amyloid light chain (AL) amyloidosis is a rare complication of Waldenström macroglobulinemia, characterized by the misfolding of lambda light chains that deposit in various organs, including the heart. We describe a case of progressive nonischemic cardiomyopathy secondary to Waldenström macroglobulinemia and IgM-associated AL amyloidosis that was refractory to medical therapy and highlight the challenges in diagnosis and management.
View Article and Find Full Text PDFMutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS).
Cancer Med
December 2024
Niguarda Hospital, Department of Hematology and Oncology, Milano, Italy.
Background: Despite recurrent and activating mutations, including MYD88, CXCR4, ARID1A, KMT2D, and CD79B were identified, the genetic basis for Waldenström's Macroglobulinemia (WM) and the risk of progression of IgM MGUS to WM remain to be fully elucidated.
Methods: We investigated the mutation status of WM (n = 8), sWM (n = 7), and IgM MGUS (n = 5) patients, by performing high-throughput targeted AmpliSeq NGS on 117 target genes. Specifically, we analyzed the CD19+ cells from 15 WM/sWM patients and five IgM MGUS patients.
Uncovering a lymphoplasmacytic lymphoma/Waldenström macroglobulinemia initially manifesting as dizziness detected through abnormal serum lipemia index: A case report.
Medicine (Baltimore)
December 2024
Department of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Rationale: Automated serum index is widely used in biochemical testing, enabling the observation of sample characteristics to a certain extent. The differences between serum lipemia index and sample characteristics can, to a certain extent, facilitate early detection of certain diseases.
Patient Concerns: This is a case report of an elderly patient who was admitted to cardiology outpatient clinic due to dizziness.
Sequential Occurrence of Eosinophilic Gastrointestinal Disease in a Case of Waldenström's Macroglobulinemia in Remission: An Unusual Report with Review.
Int J Hematol Oncol Stem Cell Res
October 2024
Apollo CBCC Cancer Care, Ahmedabad, Gujarat, India.
Waldenström macroglobulinemia (WM) is a rare lymphoproliferative malignancy presenting with para-proteinemia. The symptoms are attributable to both lymphoproliferation and IgM flare. Gastrointestinal manifestations are not uncommon.
View Article and Find Full Text PDFLymphoplasmacytic lymphoma and Waldenström macroglobulinemia, a decade after the discovery of MYD88.
Hum Pathol
December 2024
Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. Electronic address:
There has been remarkable progress over the past 80 years since Jan Waldenstrom first described patients with a hyperviscosity syndrome related to IgM paraprotein in 1944. The definition of Waldenstrom macroglobulinemia (WM) has evolved from a clinical syndrome to a distinct clinicopathologic entity with characteristic morphology, immunophenotype and molecular features. The landmark discovery of MYD88 mutation among most WM cases in 2012 marked the dawning of an era of molecular genomic exploration that led to a paradigm shift in clinical practice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!